Skip to main content

Lecanemab News

Eligibility Limited for Anti-β Amyloid mAbs in Seniors With MCI

FRIDAY, Aug. 18, 2023 – Older adults with cognitive impairment have limited eligibility for anti-β amyloid monoclonal antibodies when applying clinical trial criteria, according to a study published ...

FDA Grants Traditional Approval for Leqembi (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas...

FDA Approves Leqembi (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with Leqembi™ Treatment with Leqembi should be initiated in patients with mild c...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Alzheimer's Disease

Lecanemab patient information at Drugs.com